# Vycor Medical Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Vycor Medical Inc). ## Overview Vycor Medical Inc. is a U.S.-based medical device company focused on neurosurgical access systems and non-invasive vision rehabilitation therapies. Its business is organized around two operating units: Vycor Medical, which designs and markets the ViewSite Brain Access System for brain and spine procedures, and NovaVision, which offers computer-based therapy for patients with vision disorders caused by neurological injury. ## Products & services • ViewSite Brain Access System (VBAS) • Neurosurgical retraction and access systems • Non-invasive vision rehabilitation therapies • Computer-based therapy programs for stroke-related vision loss • Medical device design, development, and marketing - **Neurosurgical access devices** (75%) — Brain and spine surgery access and retraction systems, including VBAS. - **Vision rehabilitation therapies** (25%) — Computer-based therapies for patients with vision disorders after brain injury. - ViewSite Brain Access System (VBAS) - Neurosurgical retraction and access systems - Non-invasive vision rehabilitation therapies - Computer-based therapy programs for stroke-related vision loss - Medical device design, development, and marketing ## Customers Vycor sells primarily to hospitals and surgical users that need specialized tools for neurosurgery, especially brain and spine procedures. NovaVision serves patients with neurological vision impairment through providers, distributors, and potential digital-health partners that can reach end users efficiently. The company also targets international markets where its products are cleared or distributed through local channels. - **Hospitals and surgical centers** (primary) — Buy VBAS and related neurosurgical tools for brain and spine procedures because they need specialized access systems. - **Neurosurgeons and operating teams** (primary) — Use the access and retraction systems in procedures where precision and minimally invasive access matter. - **Vision rehabilitation patients** (secondary) — Use NovaVision therapies for vision loss caused by stroke or other brain injury. - **Healthcare distributors and partners** (secondary) — Help commercialize NovaVision and expand international access to Vycor products. - Hospitals purchasing neurosurgical access tools for brain and spine cases - Surgeons and surgical teams using VBAS in operating rooms - Patients with stroke- or brain-injury-related vision disorders - Healthcare distributors and partners extending NovaVision reach - International buyers in markets where regulatory approvals exist ## Geography Vycor is headquartered in the United States and manufactures its products and raw materials domestically. Most sales are to U.S. hospitals, but the company also exports to Canada, Japan, the UK, and the EU, making international market access an important part of the business. Regulatory approvals such as FDA 510(k) clearance and CE Marking support sales across multiple regions. - **United States** (67%) — Majority of sales are to U.S. hospitals; estimated from narrative disclosure. - **International** (33%) — Includes Canada, Japan, the UK and the EU; estimated from narrative disclosure. - United States is the main manufacturing base and largest sales market - Hospitals in the U.S. account for the majority of product demand - Exports go to Canada, Japan, the UK, and the EU - European sales depend on CE Marking and local market access - International territories matter for growth and diversification ## Strategy Vycor’s strategy centers on expanding revenue through deeper U.S. penetration, broader international distribution, and continued product development around its neurosurgical platform. The company also seeks to add complementary products and pursue partnerships or alternatives for NovaVision to extend reach without building a large direct sales force. - **Expand U.S. market penetration** (short-term) — The domestic hospital market is the core commercial base for VBAS and related products. - **Grow international distribution** (medium-term) — International markets diversify revenue and can scale the neurosurgical platform beyond the U.S. - **Partner or monetize NovaVision** (medium-term) — Partnerships can extend reach for a niche therapy platform without heavy direct commercialization spend. - **Broaden the product portfolio** (long-term) — Complementary products can increase wallet share and leverage the existing distribution network. - Increase penetration in the U.S. hospital market - Expand in under-represented international territories - Develop new products that fit broader neurosurgical use cases - Add complementary products to leverage the existing distribution base - Use partnerships for NovaVision distribution and commercialization ## Risks Vycor depends on a small number of specialized products and on hospital purchasing cycles, so adoption or reimbursement delays can affect growth. Its international business is exposed to regulatory approvals, trade tariffs, and channel execution, while NovaVision’s commercialization depends on finding effective partners or strategic alternatives. As a medical device company, it also faces product development, clinical adoption, and quality/regulatory risks that can slow market expansion. - **Dependence on VBAS and a narrow product base** [high] — A large share of the business is tied to one neurosurgical access system, so adoption changes can move revenue materially. - **International trade and tariff exposure** [medium] — The company exports to Canada, Japan, the UK and the EU, so retaliatory tariffs or trade friction could reduce international demand. - **Partner dependence for NovaVision** [high] — NovaVision’s reach relies on third parties with direct access to end users or digital-health capability. - **Regulatory and quality compliance** [high] — Medical devices require ongoing certification, clearance, and quality-system compliance to sell and maintain market access. - **Supply chain and raw material disruption** [medium] — Although products are manufactured in the U.S., raw material prices and supply availability can still be affected by global trade conditions. - Concentrated product mix makes growth dependent on VBAS adoption - Hospital purchasing cycles can delay orders and revenue timing - International sales depend on approvals, distributors, and market access - Tariffs and trade barriers could disrupt export demand - NovaVision commercialization depends on partner execution - Medical device regulation and quality requirements can slow launches ## Accounting Vycor’s reported results depend on judgment around revenue recognition for product sales and the timing of shipments to hospitals and distributors. Investors should also watch estimates tied to discontinued operations, customer credits, and any valuation or impairment judgments if the company expands through partnerships, acquisitions, or strategic alternatives. Because the business is small, quarter-to-quarter comparisons can be affected by low-volume sales and mix changes. - **Revenue recognition on product sales** — Reported sales and gross profit - **Customer credits and write-offs** — Other income and net results - **Discontinued operations** — Below-the-line operating results - **Estimates and judgments** — Assets, liabilities, revenue, and expenses - Revenue recognition timing for product shipments and sales - Quarterly volatility from low-volume orders and sales mix - Customer credits and write-offs can affect other income - Discontinued operations may create residual wind-down costs - Estimates and judgments can materially affect reported results --- *Last updated: 2026-04-29T05:07:18.748605+00:00*